Hyundai Bioscience (KRX: 048410)
Who is buying Hyundai Bioscience?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩2.8bn ($2M) of Hyundai Bioscience, the 153rd largest foreign net sale among 1828 KOSDAQ stocks. Institutions net sold ₩0.6bn ($0M) and retail investors net bought ₩4.8bn ($4M) over the same window. Foreigners were net buyers on 9 of the 20 sessions.
Foreign investors hold 6.35% of Hyundai Bioscience's listed shares (KRX ownership data as of Oct 13, 2026), down from 7.4% twenty sessions earlier and 4.48% a year ago.
The stock closed at ₩6,420 on Oct 13, 2026: -9.96% over 20 sessions, +29.31% year-to-date, +20.90% over one year. The 52-week range is ₩4,565 – ₩21,500.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩6,420 | ₩-0.7bn | +₩0.2bn | +₩0.5bn |
| 2026-10-12 | ₩6,340 | ₩-0.2bn | ₩-0.1bn | +₩0.3bn |
| 2026-10-08 | ₩6,930 | ₩-0.9bn | ₩-0.2bn | +₩1.1bn |
| 2026-10-07 | ₩7,290 | +₩0.5bn | +₩0.1bn | +₩0.3bn |
| 2026-10-06 | ₩7,150 | ₩-0.2bn | +₩0.1bn | +₩0.3bn |
| 2026-10-02 | ₩7,050 | ₩-0.3bn | ₩-0.2bn | +₩0.5bn |
| 2026-10-01 | ₩7,050 | +₩1.2bn | +₩0.3bn | ₩-1.3bn |
| 2026-09-30 | ₩6,900 | +₩0.4bn | ₩-0.2bn | ₩-0.2bn |
| 2026-09-29 | ₩6,830 | +₩0.2bn | ₩-0.3bn | +₩0.1bn |
| 2026-09-28 | ₩6,810 | ₩-0.2bn | ₩-0.2bn | +₩0.5bn |
| 2026-09-23 | ₩6,850 | +₩0.3bn | ₩-0.1bn | ₩-0.1bn |
| 2026-09-22 | ₩6,830 | ₩-0.6bn | ₩-0.2bn | +₩0.9bn |
| 2026-09-21 | ₩7,090 | +₩0.0bn | +₩0.2bn | ₩-0.2bn |
| 2026-09-18 | ₩6,800 | +₩0.2bn | ₩-0.1bn | ₩-0.2bn |
| 2026-09-17 | ₩6,660 | ₩-0.7bn | +₩0.1bn | +₩0.6bn |
| 2026-09-16 | ₩6,810 | +₩0.4bn | +₩0.1bn | ₩-0.5bn |
| 2026-09-15 | ₩6,420 | ₩-0.1bn | +₩0.3bn | ₩-0.2bn |
| 2026-09-14 | ₩6,610 | ₩-0.8bn | ₩-0.1bn | +₩0.9bn |
| 2026-09-11 | ₩6,700 | ₩-2.0bn | ₩-0.5bn | +₩2.5bn |
| 2026-09-10 | ₩7,230 | +₩1.0bn | +₩0.3bn | ₩-1.3bn |
| 2026-09-09 | ₩7,130 | ₩-7.9bn | ₩-0.2bn | +₩8.2bn |
| 2026-09-08 | ₩6,260 | +₩0.3bn | ₩-0.2bn | ₩-0.1bn |
| 2026-09-07 | ₩6,280 | ₩-0.2bn | ₩-0.1bn | +₩0.3bn |
| 2026-09-04 | ₩6,210 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-09-03 | ₩6,050 | ₩-0.3bn | ₩-0.2bn | +₩0.5bn |
| 2026-09-02 | ₩6,080 | +₩0.3bn | ₩-0.4bn | +₩0.1bn |
| 2026-09-01 | ₩6,390 | ₩-0.1bn | ₩-0.7bn | +₩0.8bn |
| 2026-08-31 | ₩6,580 | +₩0.7bn | ₩-0.6bn | ₩-0.1bn |
| 2026-08-28 | ₩6,540 | +₩0.6bn | ₩-0.1bn | ₩-0.6bn |
| 2026-08-27 | ₩6,430 | ₩-0.4bn | +₩0.1bn | +₩0.4bn |
| 2026-08-26 | ₩6,580 | +₩2.0bn | ₩-1.0bn | ₩-0.7bn |
| 2026-08-25 | ₩6,550 | +₩1.0bn | ₩-0.0bn | ₩-0.8bn |
| 2026-08-24 | ₩6,660 | ₩-0.3bn | +₩0.1bn | +₩0.2bn |
| 2026-08-21 | ₩6,650 | +₩0.3bn | ₩-0.3bn | ₩-0.1bn |
| 2026-08-20 | ₩7,090 | ₩-0.3bn | +₩0.2bn | +₩0.2bn |
| 2026-08-19 | ₩7,160 | +₩0.1bn | +₩0.0bn | ₩-0.2bn |
| 2026-08-18 | ₩7,300 | +₩0.8bn | ₩-1.1bn | +₩0.4bn |
| 2026-08-14 | ₩7,560 | ₩-0.6bn | ₩-0.6bn | +₩1.3bn |
| 2026-08-13 | ₩8,040 | ₩-0.8bn | ₩-0.2bn | +₩0.9bn |
| 2026-08-12 | ₩7,950 | ₩-1.9bn | ₩-0.3bn | +₩2.1bn |
| 2026-08-11 | ₩8,250 | ₩-0.4bn | ₩-0.7bn | +₩1.0bn |
| 2026-08-10 | ₩7,540 | ₩-3.0bn | +₩1.2bn | +₩1.3bn |
| 2026-08-07 | ₩6,790 | ₩-0.3bn | ₩-0.5bn | +₩0.7bn |
| 2026-08-06 | ₩6,890 | ₩-1.3bn | +₩0.3bn | +₩1.0bn |
| 2026-08-05 | ₩6,810 | +₩0.1bn | ₩-0.8bn | +₩0.7bn |
| 2026-08-04 | ₩6,500 | ₩-0.2bn | +₩1.5bn | ₩-1.1bn |
| 2026-08-03 | ₩6,200 | +₩0.2bn | ₩-0.2bn | ₩-0.0bn |
| 2026-07-31 | ₩5,900 | +₩1.1bn | +₩0.2bn | ₩-1.3bn |
| 2026-07-30 | ₩5,270 | ₩-0.1bn | ₩-0.1bn | +₩0.1bn |
| 2026-07-29 | ₩5,390 | +₩0.0bn | +₩0.9bn | ₩-0.9bn |
| 2026-07-28 | ₩5,790 | +₩0.1bn | +₩0.1bn | ₩-0.2bn |
| 2026-07-27 | ₩6,160 | ₩-0.3bn | +₩0.8bn | ₩-0.5bn |
| 2026-07-24 | ₩6,210 | ₩-0.4bn | ₩-0.5bn | +₩0.8bn |
| 2026-07-23 | ₩6,550 | +₩0.3bn | +₩0.7bn | ₩-1.0bn |
| 2026-07-22 | ₩5,970 | +₩0.8bn | ₩-0.5bn | ₩-0.3bn |
| 2026-07-21 | ₩6,010 | +₩0.6bn | +₩0.2bn | ₩-0.8bn |
| 2026-07-20 | ₩6,080 | +₩0.5bn | ₩-0.1bn | ₩-0.4bn |
| 2026-07-16 | ₩6,520 | +₩0.9bn | ₩-0.4bn | ₩-0.5bn |
| 2026-07-15 | ₩6,800 | +₩0.4bn | ₩-0.1bn | ₩-0.3bn |
| 2026-07-14 | ₩6,650 | +₩0.5bn | +₩0.4bn | ₩-0.9bn |
| 2026-07-13 | ₩6,950 | ₩-0.7bn | ₩-0.4bn | +₩1.1bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-0.7bn | $-1M | +₩0.2bn | +₩0.5bn |
| 5 days | ₩-1.6bn | $-1M | +₩0.1bn | +₩2.6bn |
| 20 days | ₩-2.8bn | $-2M | ₩-0.6bn | +₩4.8bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Hyundai Bioscience stock?
Over the last 5 sessions foreign investors net sold ₩1.6bn ($1M) of Hyundai Bioscience; over 60 sessions they net sold ₩10.0bn ($8M); since Jan 1, 2026 they net sold ₩16.4bn ($12M). Over 20 sessions the stock is the 153rd largest foreign net sale among 1828 KOSDAQ stocks.
How much of Hyundai Bioscience do foreign investors own?
Foreign investors own 6.35% of Hyundai Bioscience's shares as of Oct 13, 2026, versus 4.48% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩0.6bn ($0M) and retail investors net bought ₩4.8bn ($4M) of Hyundai Bioscience. Retail investors have been absorbing what foreigners and institutions are selling.
Is Hyundai Bioscience listed on KOSPI or KOSDAQ?
Hyundai Bioscience (현대바이오) trades on KOSDAQ under KRX code 048410 in the Biotech & Pharma group, with a market capitalization of ₩1T ($0.5B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩9bn ($7M) | – | -₩10bn (-$7M) | -₩14bn (-$11M) |
| 2024 | ₩15bn ($11M) | +58.70% | ₩1bn ($1M) | -₩7bn (-$5M) |
| 2025 | ₩4bn ($3M) | -76.60% | -₩18bn (-$14M) | -₩22bn (-$17M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.